Rho JK - Search Results

1

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Zhang Z, et al. Among authors: rho jk. Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330. Nat Genet. 2012. PMID: 22751098 Free PMC article.

2

p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.

Rho JK, Choi YJ, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC. Rho JK, et al. Cancer Res. 2007 Feb 1;67(3):1163-9. doi: 10.1158/0008-5472.CAN-06-2037. Cancer Res. 2007. PMID: 17283151

3

The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.

Na II, Rho JK, Choi YJ, Kim CH, Park JH, Koh JS, Ryoo BY, Yang SH, Lee JC. Na II, et al. Among authors: rho jk. Lung Cancer. 2007 Jul;57(1):96-102. doi: 10.1016/j.lungcan.2007.01.027. Epub 2007 Mar 6. Lung Cancer. 2007. PMID: 17337084

4

Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer.

Na II, Rho JK, Choi YJ, Kim CH, Koh JS, Ryoo BY, Yang SH, Lee JC. Na II, et al. Among authors: rho jk. J Korean Med Sci. 2007 Jun;22(3):393-9. doi: 10.3346/jkms.2007.22.3.393. J Korean Med Sci. 2007. PMID: 17596643 Free PMC article.

5

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH, Lee JC. Rho JK, et al. Lung Cancer. 2009 Feb;63(2):219-26. doi: 10.1016/j.lungcan.2008.05.017. Epub 2008 Jul 2. Lung Cancer. 2009. PMID: 18599154

6

HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.

Choi YJ, Rho JK, Lee SJ, Jang WS, Lee SS, Kim CH, Lee JC. Choi YJ, et al. Among authors: rho jk. J Cancer Res Clin Oncol. 2009 Aug;135(8):1047-53. doi: 10.1007/s00432-009-0543-2. Epub 2009 Jan 15. J Cancer Res Clin Oncol. 2009. PMID: 19148680

7

Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH, Yoo YD, Lee JC. Rho JK, et al. Oncol Rep. 2009 Mar;21(3):801-7. Oncol Rep. 2009. PMID: 19212642

8

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC. Rho JK, et al. Mol Cancer Res. 2009 Oct;7(10):1736-43. doi: 10.1158/1541-7786.MCR-08-0504. Epub 2009 Oct 6. Mol Cancer Res. 2009. PMID: 19808904

9

Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.

Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC. Choi YJ, et al. Among authors: rho jk. Cancer Chemother Pharmacol. 2010 Jul;66(2):381-8. doi: 10.1007/s00280-009-1174-7. Epub 2009 Nov 18. Cancer Chemother Pharmacol. 2010. PMID: 19921194

10

Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.

Kook EH, Kim YM, Kim HT, Koh JS, Choi YJ, Rho JK, Kim HR, Kim CH, Lee JC. Kook EH, et al. Among authors: rho jk. Oncol Res. 2010;18(9):445-51. doi: 10.3727/096504010x12671222663674. Oncol Res. 2010. PMID: 20524402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters